Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
Although the correlate of protection is unknown, the findings show that standard doses should be used in infants.
EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...
In the present trial, the non-inferiority margin was 0.4, meaning that efsitora wasn’t worse than degludec at reducing HbA1c. Efsitora vs degludec in adults with type 2 diabetes Like the ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback